Zobrazeno 1 - 7
of 7
pro vyhledávání: '"329"'
Autor:
Auro Viswabandya, Hans A. Messner, Dennis Dong Hwan Kim, Jieun Uhm, Marc Poch Martell, Elizabeth Shin, Jeffrey H. Lipton, Fotios V. Michelis
Publikováno v:
Blood. 126:3139-3139
Introduction: Chronic graft versus host disease (cGVHD) is one of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Several prognostic factors have been proposed to predict the outcomes of cGVHD including progres
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
Yasushi Miyazaki, Yoshihiro Hatta, Toru Sakura, Noriyoshi Iriyama, Hiroshi Handa, Masatomo Takahashi, Hisashi Sakamaki, Tomohiko Taki, Norio Asou, Shunichiro Yamaguchi, Tomoya Maeda, Shinya Satou, Shuichi Miyawaki, Sumihisa Honda, Shigeki Ohtake, Tomoki Naoe, Masafumi Taniwaki
Publikováno v:
Blood. 122:2608-2608
Background Immunophenotyping is a standard diagnostic procedure in leukemia, but unlike cytogenetic classifications, which are reliable indicators for prognostic interpretation, immunophenotyping has, thus far, yielded inconsistent results. Recently,
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the
Autor:
Myriam Rodríguez, Abel Berrios, Denisse Castro, Maria Elena Cabrera, Camila Peña, Carlos S. Chiattone, Victoria Otero, Fabiola Valvert Gamboa, Raul Gabus, Marialejandra Torres Viera, Teodoro Chisesi, Gregorio Ignacio, Brady E Beltran, Eduardo M. Sotomayor, Gabriel Borelli, Jorge J. Castillo, Sally Rose Paredes
Publikováno v:
Blood. 132:5395-5395
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world and corresponds to a heterogeneous entity, both from the clinical and molecular point of view, being its prognosis of survival very variable The
Autor:
Georg Mann, Dieter Printz, Gertraud Fröschl, Ulrike Pötschger, Gerhard Fritsch, Michael Dworzak, Helmut Gadner, Nora Mühlegger
Publikováno v:
Blood. 99(6)
Detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) predicts outcome. Previous studies were invariably based on relative quantification and did not investigate sample-inherent parameters that influence test accuracy, whi
Autor:
Susana Perdomo, Cecilia Guillermo, Lilián Díaz, Martha Nese, Alberto Baubeta, Laura Topolansky, Andrea Diaz, Mariana Stevenazzi, Ana Perdomo, Hugo Isaurralde, Graciela Lavagna, Juan Zunino
Publikováno v:
Blood. 108:5430-5430
Between 1995 and 2005, we performed 329 hematopoietic stem cell transplantation (HSCT), 286 autoulogous and 43 allogeneic. Long term results of treatment and outcome of ASCT in 100 Non Hodgkin Lymphoma (NHL) were analyzed. Median age was 47 years (ra